Patents by Inventor Hengsheng Feng
Hengsheng Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230017466Abstract: The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.Type: ApplicationFiled: September 19, 2022Publication date: January 19, 2023Applicant: PuraCap Pharmaceutical LLCInventors: Minh Tran, Yi Zeng, Zhang Julia Zhang, Hengsheng Feng, Dahai Guo
-
Publication number: 20140037550Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: October 4, 2013Publication date: February 6, 2014Applicant: TAKEDA PHARMACEUTICALS U.S.A., INC.Inventors: Matthew W. Davis, Shawn G. Watson, Hengsheng FENG
-
Patent number: 8415396Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: GrantFiled: April 20, 2012Date of Patent: April 9, 2013Assignee: Takeda Pharmaceuticals U.S.A., Inc.Inventors: Matthew W. Davis, Hengsheng Feng
-
Patent number: 8415395Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: GrantFiled: April 19, 2012Date of Patent: April 9, 2013Assignee: Takeda Pharmaceuticals U.S.A., Inc.Inventors: Matthew W. Davis, Hengsheng Feng
-
Publication number: 20120328677Abstract: An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Maher S. Kudsi, Rakeshkumar K. Lad, Hengsheng Feng
-
Publication number: 20110263716Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INCInventors: Matthew W. DAVIS, Shawn G. Watson, Hengsheng FENG
-
Patent number: 7915247Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: June 18, 2008Date of Patent: March 29, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Publication number: 20100159010Abstract: An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract.Type: ApplicationFiled: December 22, 2009Publication date: June 24, 2010Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Maher S. Kudsi, Rakeshkumar K. Lad, Hengsheng Feng
-
Patent number: 7741374Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: September 10, 2009Date of Patent: June 22, 2010Assignee: Mutual Pharmaceutical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Patent number: 7741373Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: July 13, 2009Date of Patent: June 22, 2010Assignee: Mutual Pharmacuetical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Publication number: 20090298948Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: August 21, 2009Publication date: December 3, 2009Applicant: Mutual Pharmaceutical Company, Inc.Inventors: Mathew W. DAVIS, Shawn G. WATSON, Hengsheng FENG
-
Publication number: 20090215904Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: May 13, 2009Publication date: August 27, 2009Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Matthew W. Davis, Shawn G. Watson, Hengsheng Feng
-
Patent number: 7569612Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: June 18, 2008Date of Patent: August 4, 2009Assignee: Mutual Pharmaceutical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Publication number: 20090170952Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: March 20, 2009Publication date: July 2, 2009Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Matthew W. DAVIS, Shawn G. WATSON, Hengsheng FENG
-
Publication number: 20090093548Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Type: ApplicationFiled: October 6, 2008Publication date: April 9, 2009Applicant: MUTUAL PHARMACEUTICAL COMPANY, INCInventors: Mathew W. Davis, Shawn G. Watson, Hengsheng Feng
-
Publication number: 20090074872Abstract: Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.Type: ApplicationFiled: November 20, 2008Publication date: March 19, 2009Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Publication number: 20080220076Abstract: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed.Type: ApplicationFiled: May 16, 2008Publication date: September 11, 2008Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Kristin Anne Arnold, Hengsheng Feng, Kurt R. Nielsen
-
Publication number: 20080050450Abstract: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed. In some embodiments, the active agent is fenofibrate. In other embodiments, the fenofibrate compositions are in a treatment form that that is bioequivalent to TriCorĀ® 145 mg or 48 mg.Type: ApplicationFiled: June 26, 2007Publication date: February 28, 2008Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Kristin Arnold, Hengsheng Feng, Kurt Nielsen
-
Publication number: 20060263429Abstract: A compressible mixture prepared from a waxy filler, cellulose filler, or a mixture thereof and a disintegrant is disclosed for the preparation of compressed pharmaceutical compositions containing coated pellets. The resulting compressed compositions exhibit substantially the same dissolution profiles as the pellets in the absence of the compressible mixture.Type: ApplicationFiled: May 20, 2005Publication date: November 23, 2006Inventor: Hengsheng Feng
-
Publication number: 20060204575Abstract: Amphetamine formulations comprise a plurality of particles comprising two or more pharmaceutically active amphetamine salts, wherein the dosage form, when administered under fed conditions provides a reduced variability in bioavailability as compared to the dosage form administered under fasted conditions.Type: ApplicationFiled: March 11, 2005Publication date: September 14, 2006Inventors: Hengsheng Feng, Grant Heinicke